Immunohistochemistry of DYRK2 in these patient-derived PCa tumors also demonstrated that the expression of DYRK2 in tumor tissues was much higher than in normal tissues (Fig. 1f). The gene discussed is DYRK2; the disease is posterior cortical atrophy.